| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T152 |
0-216 |
Sentence |
denotes |
Likewise, tenofovir alafenamide (Vemlidy; 2016) is an adenine-based acyclic nucleotide analog that, following activation, acts as a competitive inhibitor of reverse transcriptase and DNA chain elongation termination. |
| T153 |
217-395 |
Sentence |
denotes |
The activation of the drug is, however, different and it usually takes place in infected cells by a series of bio-transformations similar to those of remdesivir (Figure S2) [67]. |
| T154 |
396-612 |
Sentence |
denotes |
The main advantage of the prodrug, relative to the former prodrug, is that it increases the drug’s oral bioavailability, intestinal diffusion, selectivity of targeting the infected cells, and intracellular half-life. |
| T155 |
613-694 |
Sentence |
denotes |
It also decreases the potential renal toxicity of the monophosphate intermediate. |
| T156 |
695-755 |
Sentence |
denotes |
Tenofovir alafenamide was first approved in 2016 by the U.S. |
| T157 |
756-823 |
Sentence |
denotes |
FDA and is prescribed for the oral treatment of HBV infection [68]. |
| T158 |
824-1062 |
Sentence |
denotes |
It is also available in many other combinations with emtricitabine (Descovy; 2016), bictegravir and emtricitabine (Biktarvy; 2018), emtricitabine and rilpivirine (Odefsey; 2016), and darunavir/cobicistat and emtricitabine (Symtuza; 2018). |
| T159 |
1063-1352 |
Sentence |
denotes |
The efficacy of emtricitabine and tenofovir alafenamide as a prophylactic combination against SARS-CoV-2 infection is being evaluated in a large randomized, double-blind, controlled with placebo clinical trial for health care providers exposed to COVID-19 patients (NCT04405271; n = 1378). |
